非转移性去势抵抗性前列腺癌中的新一代雄激素受体抑制剂
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.
作者信息
Lavaud Pernelle, Dumont Clément, Thibault Constance, Albiges Laurence, Baciarello Giulia, Colomba Emeline, Flippot Ronan, Fuerea Alina, Loriot Yohann, Fizazi Karim
机构信息
Department of Cancer Medicine, Gustave Roussy Cancer Campus, University of Paris Saclay, Villejuif, France.
Department of Cancer Medicine, Hôpital Saint Louis, Paris, France.
出版信息
Ther Adv Med Oncol. 2020 Dec 23;12:1758835920978134. doi: 10.1177/1758835920978134. eCollection 2020.
Abstract
Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.
摘要
直到最近，对于非转移性去势抵抗性前列腺癌（nmCRPC）患者，仍建议持续进行雄激素剥夺治疗（ADT）并密切监测患者，直至病情进展为转移性去势抵抗性前列腺癌（CRPC）。由于延缓这些患者转移和症状的出现是一个主要问题，因此有多项试验在这种情况下研究了新一代雄激素受体（AR）轴抑制剂，如阿帕他胺、达罗他胺和恩杂鲁胺。本综述总结了nmCRPC治疗的最新进展，强调了新一代AR抑制剂对无转移生存期、总生存期和其他具有临床意义的终点的有利影响。
相似文献
1
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.非转移性去势抵抗性前列腺癌中的新一代雄激素受体抑制剂
Ther Adv Med Oncol. 2020 Dec 23;12:1758835920978134. doi: 10.1177/1758835920978134. eCollection 2020.
2
Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.达罗他胺联合雄激素剥夺疗法用于中国高危非转移性去势抵抗性前列腺癌患者的成本-效用分析。
Adv Ther. 2023 Mar;40(3):1087-1103. doi: 10.1007/s12325-022-02389-7. Epub 2022 Dec 26.
3
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.阿帕鲁胺对比达罗他胺用于治疗非转移性去势抵抗性前列腺癌：匹配调整间接比较的疗效和耐受性。
Adv Ther. 2022 Jan;39(1):518-531. doi: 10.1007/s12325-021-01885-6. Epub 2021 Nov 19.
4
Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.多西他赛联合阿比特龙或恩扎鲁胺治疗转移性去势抵抗性前列腺癌的临床研究进展
Cancer Med. 2023 Feb;12(3):3176-3179. doi: 10.1002/cam4.5189. Epub 2022 Aug 31.
5
Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.非转移性去势抵抗性前列腺癌的治疗：聚焦阿帕鲁胺
Cancer Manag Res. 2019 Aug 1;11:7253-7262. doi: 10.2147/CMAR.S165706. eCollection 2019.
6
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.阿帕鲁胺、达罗他胺和恩杂鲁胺用于非转移性去势抵抗性前列腺癌（nmCRPC）：一项批判性综述。
Cancers (Basel). 2022 Mar 31;14(7):1792. doi: 10.3390/cancers14071792.
7
Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.非转移性去势抵抗性前列腺癌的治疗：面对与年龄相关的合并症和药物相互作用
Expert Opin Drug Metab Toxicol. 2022 Sep;18(9):601-613. doi: 10.1080/17425255.2022.2122812. Epub 2022 Sep 16.
8
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.非转移性去势抵抗性前列腺癌的治疗：聚焦第二代雄激素受体抑制剂。
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):323-334. doi: 10.1038/s41391-020-00310-3. Epub 2021 Feb 8.
9
Darolutamide For Castration-Resistant Prostate Cancer.达洛鲁胺用于去势抵抗性前列腺癌。
Onco Targets Ther. 2019 Oct 23;12:8769-8777. doi: 10.2147/OTT.S197244. eCollection 2019.
10
Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management.非转移性去势抵抗性前列腺癌治疗中的决策与困境
Med Oncol. 2022 May 13;39(7):107. doi: 10.1007/s12032-022-01743-7.
引用本文的文献
1
Prostate Cancer Treatments and Their Effects on Male Fertility: Mechanisms and Mitigation Strategies.前列腺癌治疗及其对男性生育能力的影响：作用机制与缓解策略
J Pers Med. 2025 Aug 7;15(8):360. doi: 10.3390/jpm15080360.
2
Two Decades of Disease Evolution and Biomarker-Guided Clinical Decision Making in Metastatic Prostate Cancer.转移性前列腺癌二十年的疾病演变及生物标志物指导下的临床决策制定
Int J Mol Sci. 2025 Aug 6;26(15):7593. doi: 10.3390/ijms26157593.
3
Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer.生殖系统癌症中的分子通路：聚焦前列腺癌和卵巢癌
Cancer Cell Int. 2025 Feb 3;25(1):33. doi: 10.1186/s12935-025-03658-5.
4
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management.转移性去势抵抗性前列腺癌：治疗和症状管理的进展。
Curr Treat Options Oncol. 2024 Jul;25(7):914-931. doi: 10.1007/s11864-024-01215-2. Epub 2024 Jun 24.
5
Exploiting the DNA Damage Response for Prostate Cancer Therapy.利用DNA损伤反应进行前列腺癌治疗。
Cancers (Basel). 2023 Dec 23;16(1):83. doi: 10.3390/cancers16010083.
6
Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer.提出自噬抑制作为一种治疗策略与前列腺癌雄激素靶向治疗联合应用的理由。
Cancers (Basel). 2023 Oct 18;15(20):5029. doi: 10.3390/cancers15205029.
7
The Effect of Gene Editing by CRISPR-Cas9 of miR-21 and the Indirect Target MMP9 in Metastatic Prostate Cancer.CRISPR-Cas9 基因编辑对转移性前列腺癌中 miR-21 及其间接靶标 MMP9 的影响。
Int J Mol Sci. 2023 Oct 3;24(19):14847. doi: 10.3390/ijms241914847.
8
Transcriptomic Signature and Growth Factor Regulation of Castration-Tolerant Prostate Luminal Progenitor Cells.去势抵抗性前列腺管腔祖细胞的转录组特征及生长因子调控
Cancers (Basel). 2022 Aug 3;14(15):3775. doi: 10.3390/cancers14153775.
9
From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer.从组学到多组学方法深入分析前列腺癌的分子机制。
Int J Mol Sci. 2022 Jun 3;23(11):6281. doi: 10.3390/ijms23116281.
10
Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer.剖析去势抵抗性前列腺癌中的激素信号景观。
Cells. 2021 May 7;10(5):1133. doi: 10.3390/cells10051133.
本文引用的文献
1
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.非转移性去势抵抗性前列腺癌和达罗他胺的生存情况。
N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342.
2
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.恩扎卢胺与非转移性去势抵抗性前列腺癌的生存。
N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29.
3
Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
4
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.根治性前列腺切除术治疗前列腺癌后的短期雄激素剥夺治疗联合放疗作为挽救治疗（GETUG-AFU 16）：一项 3 期随机试验的 112 个月随访。
Lancet Oncol. 2019 Dec;20(12):1740-1749. doi: 10.1016/S1470-2045(19)30486-3. Epub 2019 Oct 16.
5
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.评估非转移性去势抵抗性前列腺癌患者达罗他胺的临床相关药物-药物相互作用和群体药代动力学：III 期ARAMIS 试验的预设和事后分析结果。
Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0.
6
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.卡巴他赛对比阿比特龙或恩杂鲁胺用于转移性前列腺癌。
N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30.
7
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.阿帕鲁胺与非转移性去势抵抗性前列腺癌的总生存期。
Ann Oncol. 2019 Nov 1;30(11):1813-1820. doi: 10.1093/annonc/mdz397.
8
Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer.寡转移去势抵抗性前列腺癌的进展导向治疗
Eur Urol Oncol. 2021 Apr;4(2):305-309. doi: 10.1016/j.euo.2019.08.012. Epub 2019 Sep 23.
9
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.前列腺特异性膜抗原配体正电子发射断层扫描在非转移性去势抵抗性前列腺癌男性中的应用。
Clin Cancer Res. 2019 Dec 15;25(24):7448-7454. doi: 10.1158/1078-0432.CCR-19-1050. Epub 2019 Sep 11.
10
Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.近期全球前列腺癌发病率和死亡率模式。
Eur Urol. 2020 Jan;77(1):38-52. doi: 10.1016/j.eururo.2019.08.005. Epub 2019 Sep 5.
Zotero 插件